

FEB 20 2014

Section B – Special 510(K) Summary

Date Summary**Was Prepared:** January 6, 2004**Submitter's Information:**

Kendall
a Division of Tyco Healthcare Group LP
15 Hampshire Street
Mansfield, MA 02048
Phone: 508-261-8000
Fax: 508-261-6644

Contact:

James Welsh
Director, Regulatory Affairs
Kendall
a Division of Tyco Healthcare Group LP
Telephone: 508-261-8532
Fax: 508-261-8461

Device Trade Name:

14.5 Fr Chronic Hemodialysis Catheter with Symmetrical Tip
(Palindrome™)

Device Common Name:

Catheter, Hemodialysis, Apheresis, Intravascular

Classification Panel: Gastroenterology**Legally Marketed Devices To Which Substantial Equivalence Is Claimed:**

The 14.5 Fr Chronic Hemodialysis Catheter with Symmetrical Tip (Palindrome™) is substantially equivalent to the Kendall's MAHURKAR MAXID 14.5 Fr Hemodialysis Catheter in intended use, materials, physical characteristics, and performance characteristics. The modifications attributed to the predicate device are (1) reconfiguration of the catheter tip to a symmetrical shape, and (2) use of a bi-furcated tunneler specifically accommodating the symmetrical tip configuration, and (3) process changes in printing and cuff bonding that are unrelated to the tip change.

Section B – 510(K) Summary

Device Description:

The 14.5 Fr Chronic Hemodialysis Catheter (Palindrome™) has a radiopaque polyurethane shaft with two large inner lumens designed in a "double D" configuration. The distal end of the catheter extends to a symmetrical tip configuration. The proximal end of the catheter shaft contains a polyurethane hub assembly and silicone extension sets.

Intended Use:

The 14.5 Fr Chronic Hemodialysis Catheter with Symmetrical Tip (Palindrome™) is intended for acute and chronic hemodialysis, apheresis, and infusion. It may be inserted either percutaneously or by cutdown.

Performance Data: Performance data for the 14.5 Fr Chronic Hemodialysis Catheter with Symmetrical Tip (Palindrome™) is compared to that of the predicate device identified in this 510(K) summary. Results of verification / validation demonstrate that the modified device is substantially equivalent to the legally marketed device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

FEB 20 2004

Mr. James Welsh
Director, Regulatory Affairs
The Kendall Company
Division of TYCO Healthcare Group LP
15 Hampshire Street
MANSFIELD MA 02048

Re: K033676

Trade/Device Name: Pallindrome™, 14.5 Fr Hemodialysis Catheter with Symmetrical Tip
Regulation Number: 21 CFR §876.5540
Regulation Name: Blood access device and accessories
Regulatory Class: III
Product Code: 78 MSD
Dated: November 17, 2003
Received: November 24, 2003

Dear Mr. Welsh:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. However, you are responsible to determine that the medical devices you use as components in the kit have either been determined as substantially equivalent under the premarket notification process (Section 510(k) of the act), or were legally on the market prior to May 28, 1976, the enactment date of the Medical Device Amendments. *Please note:* If you purchase your device components in bulk (i.e., unfinished) and further process (e.g., sterilize) you must submit a new 510(k) before including these components in your kit. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, and labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration (21 CFR Part 807); listing (21 CFR Part 807), labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on the labeling regulation, please contact the Office of Compliance at (301) 594-4616. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll free number (800) 638-2041 or (301) 443-6597, or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,


for
Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

KO33676

Indications for Use Statement

Device Name:

14.5 Fr. Chronic Hemodialysis Catheter with Symmetrical Tip (PalindromeTM)

Indications for Use:

The 14.5 Fr Chronic Hemodialysis Catheter with Symmetrical Tip (PalindromeTM) is intended for acute and chronic hemodialysis, apheresis, and infusion. It may be inserted either percutaneously or by cutdown.


Please Do Not Write Below This Line – Continue On Another Page If Needed

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use _____
(Per 21 CFR 801.109) 

OR

Over-The-Counter Use _____


(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number KO33676